Two research groups present data on Pressure BioSciences' PCT Platform at HUPO 2012

Published on November 3, 2012 at 7:34 AM · No Comments

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that scientists from two separate research groups presented data at the recent HUPO 11th Annual World Congress (Boston, MA) indicating that the incorporation of the Company's Pressure Cycling Technology ("PCT") Platform into their sample preparation processes resulted in a marked improvement in the quality and/or efficiency of test results.  These studies were presented by scientists from the Center for Biologics Evaluation and Research of the Food and Drug Administration ("FDA") and from Janssen Research and Development ("Janssen").

Dr. Michail Alterman and colleagues from the FDA presented on the "Global Proteomic Architecture of Culture-Expanded Human Bone Marrow Multipotent Stromal Cells (MSCs) and the Proteomic Basis of Heterogeneity".  MSCs are believed to offer huge potential for cell-based therapies for a wide variety of diseases.  Currently, MSC studies are primarily focused on highly abundant proteins, which are generally unable to reveal important cellular events.  The authors presented on the use of a highly improved approach to sample preparation and protein identification.  This approach allowed them to better identify and analyze events likely to control the biology of the MSCs.  Such information could be essential in the design and development of new, life-saving cell-based therapies. The authors reported that PCT was an important part of their improved sample preparation approach. 

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post